8 Biotech Stocks Facing FDA Decisions In February
As January comes to a close, which biotech stocks await FDA decisions in February that could serve as catalysts?
This Biotech Laggard Could Offer Traders A Market-Beating Opportunity
When it comes to the performance of healthcare companies during the pandemic, the author of today’s article notes that “Those best prepared for developing a… Read More »This Biotech Laggard Could Offer Traders A Market-Beating Opportunity
“Real Businesses Producing Real Cash”: 3 Penny Stocks Poised To Benefit From Major Market Trends
“Investors who want the massive potential gains from penny stock investing should focus on those with a real business producing real cash,” advise the authors… Read More »“Real Businesses Producing Real Cash”: 3 Penny Stocks Poised To Benefit From Major Market Trends
Is Novavax A Buy Right Now? A Look At The Stock And Its Coronavirus Vaccine Candidate
Over the course of the past 12 months, Novavax has gone from penny stock status before the pandemic to skyrocketing more than 2,700% over the course of the pandemic thus far.
These 4 Biotech Penny Stocks Are Buys, According to Analysts
Four biotech penny stocks with upside to analyst price targets ranging from 42% to 291%.
5 Buy-Rated Stocks Priced Under $10 Offering Solid Alpha Potential
or these five stocks – which include a smaller cap mining company and a small-cap biotech play focused on developing specialty products for underserved patient populations read more!
This Recent Biotech IPO Has The Right Story At The Right Time – And The Right Pattern
The author of today’s article notes that high-profile IPOs typically follow a pattern – and given this pattern, he is bullish on “a biotech stock that went public just under a month ago with a story that perfectly fits the times, and whose stock has followed exactly that pattern.”
Insights On Genomics, Electric Vehicles, Blockchain And More From The Top Stock Picker Of 2020
2020 Top Stock Picker shares insights on the outlook for genomics, electric vehicles, blockchain technology and more.
Small- And Mid-Cap Biotech Picks For 2021
Small- And Mid-Cap Biotech Picks For 2021 and holdovers from 2020.
How To Capitalize On What Could Be “The Best Decade, Ever, For The Stock Market”
Now, as 2021 begins, the author of today’s article believes that the “next decade could easily be the best decade, ever, for the stock market as post-war euphoria and easy money policy couple with multiple hypergrowth technological breakthroughs to rapidly unlock tremendous and widespread economic value.”